Search result

About us

CHIESI USA Improving the lives of people with acute, rare and chronic disorders. Chiesi USA, Inc., headquartered in Cary, NC, is an affiliate of Chiesi Farmaceutici S.p.A, a family-owned, global R&D-focused pharmaceutical company based in Parma, Italy. We are a specialty pharmaceutical...

History

CHIESI USA Chiesi USA was established in 2014 with the acquisition of Cornerstone Therapeutics Inc., as the culmination of a strong strategic alliance first formed in 2009. The organizations shared a focus on their people and a desire to address unmet medical needs in the specialty...

Mission & values

Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life. We wish to maintain a high quality entrepreneurial team characterised by self-confidence and a...

Our Management

-

Compliance

Chiesi USA, Inc. (the “Company”) has a Comprehensive Compliance Program that reflects the Company’s commitment to compliance with the full range of laws, regulations and policies that govern pharmaceutical marketing and selling activities in the United States. The Company’s...

Sunshine Act Compliance

The Sunshine Act, or National Physician Payment Transparency Program (Open Payments), is a section of the Patient Protection and Affordable Care Act of 2010. This program requires manufacturers of pharmaceuticals, medical devices and biologics that participate in U.S. federal health care programs...

Products

Chiesi USA: Elevating the experience of managing each patient’s condition. Chiesi USA is committed to developing and commercializing products that meet the needs of healthcare providers and their patients. We deliver our products and associated services to improve the treatment of...

Clinical transparency

Clinical Trial Transparency As European Federation of Pharmaceutical Industries and Associations (EFPIA) members, Chiesi Group companies are committed to clinical trial transparency. All Chiesi studies are recorded on www.clinicaltrials.gov. Scientific Journal Publication Chiesi is also...

News

-

Sustainability

Our Commitment Sustainability has always been at the core of our ethical commitment. Our goal is to translate this commitment into results with integrity while operating in a socially and environmentally responsible manner, thus creating Shared Value. We strive to create Shared Value by...

Expanded access programs

Chiesi USA, Inc. Expanded Access Programs Expanded Access, sometimes referred to as compassionate use, may be an option for certain individuals with serious or life-threatening conditions or diseases who have no satisfactory or comparable alternative therapy to treat the disease or condition...

Privacy-SpeakUp&BeHeard

PRIVACY NOTICE This privacy notice is provided by Chiesi Farmaceutici S.p.A., including its affiliates (together “Chiesi Group“ or “Chiesi”) in compliance with the applicable privacy regulations and is aimed at informing the reporting individuals on how we process...

Join Our Team

Our culture belongs to the brave and the curious. At Chiesi we focus on finding innovative solutions and embracing new challenges. Every choice we make is driven by the will to generate a positive impact both on our community and our planet. Meaningful Work Our work is...

Our People & Culture

OUR PEOPLE AND CULTURE Diverse Talent Chiesi USA is an equal opportunity employer committed to hiring a diverse work force at all levels of our business. Our environment encourages each individual to reach his or her full potential and drive outstanding results. All qualified...

Our Pay and Benefits

At Chiesi, we are passionate about delivering on our promise of work-life harmony. We recognize the whole person: at work, in the family, and throughout life’s changing landscape. People are our most valuable asset, and we will always be committed to taking actions that ensure our...

Current Openings

Thank you for your interest in joining Chiesi USA, Inc. (“Chiesi”). Chiesi USA, Inc., is a B Corp and Public Benefit Corporation company awarded Top Employer status for eight consecutive years and is currently certified as a Great Place to Work®. We are always searching for...

Contact Us

Headquarters (USA) Chiesi USA, Inc.175 Regency Woods Place, Suite 600, Cary, NC 27518 IF YOU NEED IMMEDIATE MEDICAL ASSISTANCE, PLEASE DIAL 911. Please select the best contact method for your inquiry: General Information (including an employee directory)...

Patient Support

Chiesi USA seeks to provide access to our therapies for all patients, especially for those most in need. If you are experiencing financial hardship, you may be eligible to receive assistance from one of our Copay Assistance Programs. Alternative programs may be available for...

Business Development

Building a foundation. Improving patient lives. Delivering results. Chiesi USA, Inc. is always seeking new opportunities to drive future growth through strategic acquisitions of companies, existing marketed or registration-stage products and late-stage development products. We welcome...

Grant Program

At Chiesi USA, we are committed to supporting U.S.-based educational efforts of the medical communities we serve. Our grant program funding focuses on the following areas: Independent medical education Healthcare-related charitable support Scientific project support Medical...

Compliance Concerns

REPORTING CONCERNS You may anonymously report potential violations of Chiesi’s corporate compliance and ethics programs by calling the Company’s corporate governance hotline at 1-877-212-4562. If you wish to report a complaint, you are invited to communicate with our...

Medical Inquiries

Have a question related to our medicines? A member of the Chiesi USA Medical Information team would be happy to help. Request can be submitted to a Chiesi Medical Information team member by using the following form, or via the email address or phone number listed at the bottom of this...

Sitemap

-

Privacy

This Privacy Notice is effective as of July 17, 2023.This Privacy Notice was last reviewed on July 17, 2023.In this Privacy Notice (the “Notice”), Chiesi USA, Inc., with offices at 175 Regency Woods Place, Suite 600, Cary, NC 27518 (“Chiesi” or “we”), describes...

Terms of use

The information provided on this Internet Web site (“Site”) is for general informational and educational purposes only. Please read and review these Terms of Use carefully before accessing or using this Site. By accessing or using this Site, you acknowledge that you have read,...

Search result

-

Credits

This project was edited and produced by Dynamic Mind.

Web Resource Unavailable

The server hosting this resource is temporarily down for maintenance. Please try again later.Maintenance date: //

About us

-

Mission & Values

-

Management

-

Press Releases

-

About Rare Diseases

The term rare applies to those diseases affecting a limited number of people with a prevalence below a given cut-off point, which is codified by the legislation of each individual country.

Lysosomal Storage Disorders

Lysosomal storage disorders (LSDs) are a group of about 50 rare inherited metabolic disorders that result from defects in lysosomal function. New lysosomal storage disorders continue to be identified every day. They are characterized by an abnormal build-up of various toxic...

Rare Hematologic

Beta thalassemia and sickle cell disease are two disorders that affect red blood cells.Both conditions cause problems with hemoglobin, depriving many parts of the body of oxygen.Both conditions can also lead to serious complications, and, furthermore, both conditions are without a cure.1-4 We...

Rare Ophthalmologic

Leber’s Hereditary Optic Neuropathy (LHON) is a rare ophthalmologic condition caused by mutations in mitochondrial DNA.1 Of the mitochondrial DNA disorders, LHON is the most common.2 Adults with this condition develop permanent subacute central vision loss in both eyes, which has a...

Pipeline

-

Fabry Disease

Fabry disease is a lysosomal storage disorder, meaning that a glycosphingolipid called GL-3 accumulates in the lysosomes, causing tissue damage; many cell types are affected.1 The disease is caused by mutations in the GLA gene, resulting in nonfunctional or dysfunctional alpha-galactosidase A, a...

Alpha-mannosidosis

Alpha-mannosidosis is a rare, genetic disease, caused by the impaired function of the lysosomal enzyme alpha-mannosidase.1 Due to this deficiency, oligosaccharides are only partially broken down and over time they build up in the body, causing increasing damage to cells and leading to medical...

Nephropathic Cystinosis

-

Beta-Thalassemia

-

Leber’s Hereditary Optic Neuropathy

LHON is the most common inherited mitochondrial (mt) DNA disorder.1

Partnerships

See What we are looking for

Patient advocacy

-

Description

-

Patient Organization Links

-

Our locations

-

Products

Chiesi Rare Diseases is committed to developing and commercializing products that meet the needs of healthcare providers and their patients. We deliver our products and associated services to improve the treatment of patients with rare diseases. We are also dedicated to investing in...

Sustainability of the Supply Chain

The UN Global Compact defines Supply Chain sustainability as “the management of environmental, social, and economic impacts, and the encouragement of good governance practices throughout the lifecycles of goods and services”. This definition underscores the...

Home

-

Accessibility

Chiesi USA, Inc. is committed to making our website's content accessible and user friendly to everyone.If you are having difficulty viewing or navigating the content on this website, or notice any content, feature, or functionality that you believe is not fully accessible to people with...

Pipeline

A BALANCED AND TARGETED PIPELINE The number of ongoing research programs continues to increase year after year. Chiesi USA is predominantly focused on the key areas of respiratory, neonatology, and special care. RESPIRATORY The respiratory area is the hub of Research...

Cookie

Cookies are small text files stored on your browser when using websites or applications. You can control how the use of cookies by websites configuring privacy settings in the browser (see the browser's help to learn more about the cookie control). Note that if you disable cookies altogether, Web...

Chiesi acquires ApoPharma

-

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

CARMIEL, Israel, May 28, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

CARMIEL, Israel, May 28, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

Deal provides Chiesi Group with worldwide, exclusive license to use Bioasis xB3 TM platform for delivery of undisclosed enzymes in treatment of four lysosomal storage disorders. Under terms of the agreement, Bioasis will receive an upfront payment of US$3 million, additional potential...

Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

Deal provides Chiesi Group with worldwide, exclusive license to use Bioasis xB3 TM platform for delivery of undisclosed enzymes in treatment of four lysosomal storage disorders. Under terms of the agreement, Bioasis will receive an upfront payment of US$3 million, additional potential...

Bioasis and Chiesi Group to Host Webcast on July 16, 2020

GUILFORD, CONN., U.S.A. and PARMA, ITALY – BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TMplatform technology for the delivery of therapeutics across the blood-brain...

Bioasis and Chiesi Group to Host Webcast on July 16, 2020

GUILFORD, CONN., U.S.A. and PARMA, ITALY – BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TMplatform technology for the delivery of therapeutics across the blood-brain...

Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group

Parma, July 2, 2020 – Thomas Eichholtz is the new Head of Global Research and Development at the Chiesi Group. A senior leader with over 25 years’ experience in Research and Development across the entire value chain, from target identification to registration and post-marketing...

Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the ProposedTreatment of Fabry Disease

Top-line data anticipated in 4Q2020 upon completion of final monitoring visits CARMIEL, Israel, August 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant...

Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the ProposedTreatment of Fabry Disease

Top-line data anticipated in 4Q2020 upon completion of final monitoring visits CARMIEL, Israel, August 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review

CARMIEL, Israel, Aug. 11, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®...

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)

CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international...

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).

CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international...

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Program grants access to investigational treatment for Fabry disease patients that cannot be adequately treated with any FDA-approved drugs and provides guidance to treating physicians BOSTON and CARMIEL, Israel, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review

CARMIEL, Israel, Aug. 11, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

Phase III BRIDGE open-label, switch-over clinical trial met key objectives for safety and efficacy Mean overall annualized change in estimated Glomerular Filtration Rate (eGFR slope) improved from -5.9 to -1.2 mL/min/1.73 m2/year 12-months on-treatment Phase III BRIDGE study final results...

Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease

Program grants access to investigational therapy for Fabry disease patients in the United States who cannot be adequately treated with currently available FDA-approved drugs - Boston, MA, (December 23, 2020) – Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

CARMIEL, Israel, November 27, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based...

Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease

- Approval is based on demonstrated reduction in liver iron concentration – - Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia - BOSTON, Mass. – May 1, 2021 - Chiesi Global Rare Diseases, a business unit of Chiesi...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Phase III BRIDGE open-label, switch-over clinical trial met key objectives for safety and efficacy Final analysis confirmed substantial improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate (eGFR slope) in patients switched from agalsidase...

Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support

Company sponsors #wewearstripes social media campaign calling on participants to share photos to express support for people affected by rare diseases Company to light up offices around the world including Italy, the United States, and Canada BOSTON, Mass. - February 26, 2021 -...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease

Study achieved key objectives for safety, efficacy and pharmacokinetics After completion of the study, all patients enrolled in an extension study pegunigalsidase alfa (PRX-102) provided coverage to patients for the entire 4‑week period in treated patients No new...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA

CARMIEL, Israel and BOSTON, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Chiesi Global Rare Diseases Announces Updated U.S. Prescribing Information for FERRIPROX® (deferiprone)

BOSTON, Dec. 3, 2021 /PRNewswire/ – Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the FERRIPROX® (deferiprone) Prescribing Information in the U.S. has been...

Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Brazil for the Treatment of Iron Overload in Sickle Cell Disease

ANVISA also approves FERRIPROX in combination with other iron chelators in thalassemia major when monotherapy is ineffective BOSTON, Mass. – September 13, 2021 - Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare...

Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the Treatment of Iron Overload in Sickle Cell Disease

BOSTON, Mass. – October 15, 2021 – Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that Health Canada has approved FERRIPROX® (deferiprone) for the treatment of iron...

Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease

CARMIEL, Israel and BOSTON, October 11, 2021 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease

CARMIEL, Israel and BOSTON, October 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice-a-day tablets

BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone)...

Chiesi Global Rare Diseases Recognizes Fabry Disease Awareness Month and Launches “Fabry Focus on Health” Educational Series to Support Patients and Caregivers During COVID-19 Pandemic

Program offers suggestions from leading clinicians and other experts regarding impact of COVID-19 on families affected by Fabry disease BOSTON, April 24, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A. focused on research and development of...

Chiesi USA increases support measures for employees, patients and community partners in response to COVID-19 pandemic

Chiesi USA implemented increased health and well-being measures to support employees.Chiesi’s production line and supply chain are operating with no disruption across the network.Chiesi USA has committed $50,000 in support to Triangle nonprofit partners during the COVID-19 outbreak, and Chiesi...

Chiesi USA certified as a Great Place to Work® in 2019

Employee-driven recognition reaffirms Chiesi as a top employer in the U.S. and in life sciences industryCARY, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, has earned the Great Place to Work® Certification for 2019 in the...

Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease Companies Announce Topline Results from Interim Analysis of Phase III BALANCE Clinical Trial

Protalix management to host conference call and live webcast today at 8:30 am EDT CARMIEL, Israel and BOSTON, Mass. – June 2, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production...

Chiesi USA, Inc. Earns 2021 Life Sciences Award by Triangle Business Journal for second consecutive year

Chiesi recognized for its continued service to patients, healthcare providers, employees and community partners during the COVID-19 pandemic Cary, North Carolina, May 24, 2021 – Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused...

Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020

Chiesi Group recently announced launch of new Chiesi Global Rare Diseases division to address significant unmet needs in rare diseasesDivision to advance research and build partnership opportunities with global leaders in patient education and support BOSTON, Feb. 27, 2020 (GLOBE NEWSWIRE) --...

Chiesi Global Rare Diseases Launches “Rethink Fabry” Campaign to Bring Important Information to Fabry Disease Community and Support Patients and Caregivers

Disease education program aims to help patients, caregivers and families affected by Fabry disease to make informed healthcare decisions Program includes new resources for healthcare professionals to support strategies in diagnosis and disease management BOSTON, Oct. 13, 2020 (GLOBE NEWSWIRE)...

Chiesi Group announces performance growth in 2020

Chiesi Group currently employs 6,389 people worldwide, 2,119 of whom are in Italy, and has a turnover of €2.229 billion.Chiesi’s business comprises 30 affiliates, seven research centers, three production sites and a commercial presence in a total of 90 countries.These results are confirmation...

Chiesi USA, Inc. announces Commercial Availability of Bronchitol® (mannitol) inhalation powder for improvement in pulmonary function in adult patients with cystic fibrosis

Phase 3 clinical trial data published in the Journal of Cystic FibrosisCARY, N.C., March 17, 2021 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the launch of FDA-approved...

Chiesi USA Announces Sponsorship of ASHP Foundation’s Pharmacy Leadership Scholars Program

Program advances research in diversity, equity and inclusion in healthcareCARY, N.C., March 16, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today its sponsorship of...

Chiesi USA donates more than $800,000 in 2020

Chiesi’s CSR program Chiesi in the Community provides significant contributions to the Triangle community and patient-focused nonprofits during the COVID-19 pandemicCARY, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an...

Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2021

Top Employer Institute recognizes Chiesi USA for the sixth consecutive yearCARY, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the company...

Chiesi USA Announces Key Promotions to Business Unit Leads

Jason Beyer to lead Neonatology and Cystic Fibrosis Business Unit, and Jay Meyer to lead Cardiovascular Hospital Business Unit as company advances U.S. therapeutic effortsCARY, N.C., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an...

Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease

- Program grants access to investigational therapy for Fabry disease patients in the United States who cannot be adequately treated with currently available FDA-approved drugs - BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A.,...

Chiesi USA Appoints Jon Zwinski as General Manager and Chief Executive Officer

Jon Zwinski succeeds Ken McBean as company advances global therapeutic efforts CARY, N.C., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has announced the...

Chiesi USA, Inc. Supports March of Dimes Eastern North Carolina in Observance of Prematurity Awareness Month

CARY, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), a specialty pharmaceutical company based in Cary, N.C., is proud to once again support March of Dimes in its mission to improve the health and lives of moms and babies during November’s Prematurity Awareness Month...

Chiesi USA, Inc. Earns Fourth Consecutive Corporate Philanthropy Award by Triangle Business Journal

Chiesi in the Community’s 2019 efforts total more than $980,000 and 2,400 volunteer hours for patient and community partnersCARY, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), a specialty pharmaceutical company based in Cary, N.C., earned the Triangle Business Journal’s...

Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder

Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF)CARY, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group...

Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)

Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi, a fundamental pillar of the company who shaped its history alongside his brother Alberto. Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate Research and...

Chiesi USA, Inc. Earns 2020 Life Sciences Award by Triangle Business Journal

Chiesi recognized for its continued service to patients, healthcare providers, employees and community partnersCARY, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), a specialty pharmaceutical company based in Cary, North Carolina, was named Company of the Year by the Triangle...

Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019

Chiesi Group reports €1,992.81 million in revenue, around 6,000 employees, an 11% reduction in CO2 emissions and more than a fourfold increase in renewable energy consumption.The report, which is based on the approach of renowned U.S. economist and essayist Jeffrey Sachs, includes Chiesi’s...

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Program grants access to investigational treatment for Fabry disease patients that cannot be adequately treated with any FDA-approved drugs and provides guidance to treating physiciansBOSTON and CARMIEL, Israel, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of...

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences

New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a Certified B Corporation™ businessPatients’ experiences and perception of Chiesi at the heart of the new corporate identity CARY, N.C., March 22, 2021 (GLOBE NEWSWIRE) -- Chiesi USA...

Chiesi Group calls for #ActionOverWords in the fight against climate change

Chiesi Group, the largest international pharmaceutical company Certified B Corporation™, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability. CARY, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Chiesi USA...

Chiesi USA Appoints VP of Medical Affairs to Support Continued Growth

Martin Marciniak, RPh, MPP, PhD, appointed as Vice President of Medical AffairsCARY, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has appointed Martin...

Chiesi accelerates path toward full sustainability despite COVID-19 pandemic

Ensuring continuing medical treatment for patients has been top priority during COVID-19 pandemic.Focus on Diversity & Inclusion in the workplace: 53% of all employees are women – ratio of female workers even higher in R&D (64%).All the company’s 2020 activities, data and figures are...

Chiesi USA announces new organizational leadership for the Chiesi Foundation

Maria Paola Chiesi, former Coordinator of the Foundation since 2010, succeeds Dr. Paolo Chiesi CARY, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), announced that Maria...

Chiesi USA Donates nearly $15,000 to Three Triangle Nonprofits through Partnership with Durham Bulls

Partnership spotlights Triangle nonprofits as the true champions with Chiesi as the 2021 presenting strikeouts sponsor CARY, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- As the Durham Bulls took down the Norfolk Tides on September 12, Chiesi USA (key-A-zee), a Cary-based specialty pharmaceutical...

Chiesi USA Announces Publication of Cost-Consequence Analysis of KENGREAL® (cangrelor) in Cardiac Patients at High Risk of Complications Following PCI in the American Journal of Cardiovascular Drugs

CARY, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the publication of a cost-consequence analysis of KENGREAL® (cangrelor) in patients receiving...

Chiesi USA Promotes Polly Petrino to VP, Finance and Member of Leadership Team

Finance leader with more than 20 years of expertise will lead finance, administrative and contracting functions CARY, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), a Cary-based specialty pharmaceutical company, has announced the promotion of Polly Petrino to Vice President,...

A new clinical framework redefines the diagnosis of COPD Exacerbations

The recommendations of an international expert panel to update the definition and severity classification of chronic obstructive pulmonary disease (COPD) exacerbations will be presented by Professor Bartolome R. Celli at the 2021 International Meeting on Asthma and COPD in FlorencePhysicians will...

Chiesi Group Continues to Grow In 2021

Chiesi Group turnover of €2.42bn supported by strong international growth of 8.6%Growth across global markets, with U.S. up more than 10% and China up 22%Continued focus on innovation: Chiesi invests nearly 20% of turnover in R&D in 2021Chiesi recognized as Top Employer in eight global...

Chiesi USA donates more than $815,000 to local communities and nonprofits in 2021

Chiesi in the Community, Chiesi’s CSR initiative, provides significant contributions to the Triangle community and patient-focused nonprofitsCARY, N.C., March 16, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, contributed more than $815,000...

Chiesi USA certified as a Great Place to Work® in 2021

Employee-led assessment affirms Chiesi USA’s strong performance in culture, leadership, values and trust CARY, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, has earned the Great Place to Work® Certification for 2021 in the...

Chiesi USA Announces New Publication of Post Hoc Analysis on Timing of Ischemic Events in Cardiac Patients and Role of KENGREAL® (cangrelor) in Reducing Risk

Post hoc analysis of the CHAMPION PHOENIX clinical trial demonstrates that the majority of ischemic events occurred early in percutaneous coronary intervention (PCI), and KENGREAL® (cangrelor) treatment significantly reduced these events in the first two hours post-randomization compared to...

Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2022

Chiesi USA celebrates seven consecutive years of recognition from the Top Employers Institute CARY, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group),...

Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL® (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice

The CAMEO registry, an ongoing study to provide real-world data on KENGREAL® (cangrelor), has published interim results in the Journal of the American Heart Association.This analysis from CAMEO is the first analysis of its kind to describe acute medication administration in a percutaneous coronary...

Chiesi tracks actions taken for a healthier, more sustainable future

Chiesi’s Annual and Sustainability Report 2021 is released today;Progress toward business, environmental and social targets is strong;Company is joining forces with all stakeholders to advance sustainable healthcare. CARY, N.C., July 14, 2022 (GLOBE NEWSWIRE) -- Chiesi, the international...

Chiesi Group joins White House pledge to decarbonize healthcare sector

Chiesi Group signed the HHS Health Care Sector Climate Pledge to achieve even greater progress on climate resilienceThe White House cited Chiesi’s leadership in exceeding the pledge by tackling emissions from fluorinated gases used in common devices like inhalers, with the goal of reducing their...

Chiesi USA Reports Progress in ASHP Foundation’s Pharmacy Leadership Scholars Program

Chiesi USA sponsored the innovative ASHP Foundation Pharmacy Leadership Scholars program, awarding $50,000 in grants to five early-stage pharmacist researchers CARY, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an...

Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome

This cost-consequence analysis suggests selective early rescue surfactant administration strategies are associated with a lower healthcare burden in premature infants with RDS. CARY, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an...

Chiesi Group joins Biden Administration pledge to decarbonize health care sector, make facilities resilient to climate change

Chiesi Group’s leadership recognized by Administration officials at COP27 CARY, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chiesi Group, the international research-focused biopharmaceutical group, was celebrated by the U.S. Department of Health and Human Services (HHS) at the 2022 United Nations...

Chiesi USA Chosen as One of Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals

Chiesi USA recognized for its dedication to ensuring that employee voices are heard and valued CARY, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has been...

Chiesi USA Partners with Durham Bulls to Donate $15,000 to Three Triangle Nonprofits

Partnership is a home run as donations make a positive difference in the lives of North CaroliniansCARY, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), a Cary-based specialty pharmaceutical company, felt like part of the team as the company concluded its presenting strikeout...

Chiesi is Recertified as a B Corp and Sets New Tougher Objectives for Action by 2025

The Group has increased its B Impact score by 16.3 points, with 103.8 out of 200 compared to its first certification in 2019The recertification process by B Lab identifies further focus for action and continuous improvement. CARY, N.C., Sept. 22, 2022 (GLOBE NEWSWIRE) -- The B Corp movement,...

2022 for Chiesi: The Group’s international growth continues

Turnover at €2 billion 749 million, with growth of 13.6% over 2021The European market remains at the center, with significant international developmentThe distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare diseases) 12% and Care...

Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention

As a Certified B Corporation™, Chiesi deepens ASHP partnership to fund educational efforts designed to address the pharmacy technician shortage and support pharmaceutical professionals. CARY, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi...

Chiesi USA donates more than $830,000 to local communities and nonprofits in 2022

Chiesi’s CSR initiative, Chiesi in the Community, was determined to out-do itself in another year of meaningful community impact.2022 efforts include deepened partnerships with Triangle-area nonprofits for children and families, as well as organizations advancing DE&I and patient support in...

Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR

Richard Smith brings 25 years of expertise in building commercial excellence and partnering with the healthcare community across multiple therapeutic areasChiesi USA remains steadfast in its preparations for the full-scale U.S. launch of its AIR franchise as part of the company’s commitment to...

Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023

Chiesi Group announces mid-year turnover of €1,497 millionSubstantial growth of each of Chiesi’s business areasEurope remains the biggest market, followed by the U.S. and ChinaForecasted revenues of about €3 billion for 2023, with an additional solid growth expected in 2024 CARY, N.C., Aug. ...

Chiesi USA Partners with Smith Anderson to Host 1L Excellence in Diversity Fellow this Summer

Duke University School of Law student Cecilia Poston will work alongside Chiesi’s legal team to support her early career development and advance diversity, equity and inclusion in the professionCARY, N.C., June 12, 2023 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty...

Chiesi USA CEO Appointed to ASHP Foundation Board of Directors

CEO Jon Zwinski to serve a two-year term on the Board of Directors starting in June 2023, deepening the partnership between Chiesi and ASHPCARY, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, announced today that Jon Zwinski,...

BETHKIS® (Tobramycin Inhalation Solution)

-

CLEVIPREX® (clevidipine) injectable emulsion

-

CUROSURF® (poractant alfa) Intratracheal Suspension

-

KENGREAL® (cangrelor) for injection

-

RETAVASE® (reteplase) for injection

-

Ferriprox

-

BRONCHITOL® (mannitol) inhalation powder

-

Search results